ABSTRACT
OBJECTIVE: This study retrospectively examined the association between cancer-related fatigue (CrF) and the number of falls during the last 12 months in patients with myeloproliferative neoplasms (MPNs). METHODS: A multicenter, 1-time anonymous survey was conducted using analog and digital questionnaires. Sex-stratified multinomial logistic regression analysis was applied to investigate the association between CrF and number of falls. All analyses were adjusted for age, school education, body mass index, MPN subtype, and quality of life. RESULTS: The final sample comprised 688 patients (mean age 57.4 ± 13.8, 62.4% women). The fall rate was 16.2% in women and 12.2% in men (P = .153). There were no differences between women and men in terms of CrF between individuals with more than 1 fall, whereas women with 1 fall had a higher CrF compared to those without a fall (RRR = 1.019; 95% CI [1.002-1.039]), respectively. CONCLUSION: CrF increases the risk of falls in women with MPN. Physicians should evaluate and manage CrF symptoms and implement fall prevention strategies for those who are at increased risk. Further research is needed to better understand the effects of CrF on gait performance and associated fall risk.
Subject(s)
Hematology , Myeloproliferative Disorders , Neoplasms , Male , Humans , Female , Accidental Falls/prevention & control , Cross-Sectional Studies , Quality of Life , Retrospective Studies , Neoplasms/epidemiology , Neoplasms/complications , Myeloproliferative Disorders/complications , Myeloproliferative Disorders/epidemiology , Fatigue/epidemiology , Fatigue/etiologyABSTRACT
Relapse is a major cause of treatment failure after allogeneic hematopoietic cell transplantation (allo-HCT) in myeloid malignancies. Additional strategies have been devised to further maximize the immunologic effect of allo-HCT, notably through maintenance therapy with hypomethylating agents such as 5-azacytidine (AZA). We conducted a single-center retrospective study to investigate the efficacy of AZA after allo-HCT for high-risk myeloid malignancies. All patients transplanted between Jan 2014 and Sept 2019 for high-risk acute myeloid leukemia (n = 123), myelodysplastic syndrome (n = 51), or chronic myelomonocytic leukemia (n = 11) were included. Patients who died, relapsed, or developed grade ≥ 2 acute graft-versus-host disease before day + 60 were excluded, as well as those who were eligible for anti-FMS-like tyrosine kinase 3 maintenance. Of the 185 included patients, 65 received AZA while 120 did not. Median age at transplant was 59 years; 51.9% of patients were males. The median follow-up was 24 months for both groups. Regarding main patient characteristics and transplantation modalities, the two groups were comparable. In multivariate analyses, there were no significant differences between the two groups in terms of 2-year cumulative incidence of relapse (HR = 1.19; 95% confidence interval (CI) 0.67-2.12; p = 0.55), overall survival (HR = 0.62; 95%CI 0.35-1.12; p = 0.12) and event-free survival (HR = 0.97; 95%CI 0.60-1.58; p = 0.91) rates. In conclusion, single-agent AZA does not appear to be an optimal drug for preventing post-transplant relapse in patients with high-risk myeloid malignancies. This study highlights the need for prospective studies of alternative therapies or combination approaches in the post-transplant setting.
Subject(s)
Graft vs Host Disease , Hematopoietic Stem Cell Transplantation , Leukemia, Myeloid, Acute , Myeloproliferative Disorders , Neoplasms , Azacitidine/therapeutic use , Female , Graft vs Host Disease/etiology , Graft vs Host Disease/prevention & control , Hematopoietic Stem Cell Transplantation/adverse effects , Humans , Leukemia, Myeloid, Acute/complications , Leukemia, Myeloid, Acute/drug therapy , Male , Myeloproliferative Disorders/complications , Neoplasms/complications , Prospective Studies , Recurrence , Retrospective Studies , Transplantation Conditioning/adverse effectsABSTRACT
The unraveling of the pathophysiology of acute myeloid leukemia (AML) has resulted in rapid translation of the information into clinical practice. After more than 40 years of slow progress in AML research, the US Food and Drug Administration has approved nine agents for different AML treatment indications since 2017. In this review, we detail the progress that has been made in the research and treatment of AML, citing key publications related to AML research and therapy in the English literature since 2000. The notable subsets of AML include acute promyelocytic leukemia (APL), core-binding factor AML (CBF-AML), AML in younger patients fit for intensive chemotherapy, and AML in older/unfit patients (usually at the age cutoff of 60-70 years). We also consider within each subset whether the AML is primary or secondary (therapy-related, evolving from untreated or treated myelodysplastic syndrome or myeloproliferative neoplasm). In APL, therapy with all-trans retinoic acid and arsenic trioxide results in estimated 10-year survival rates of ≥80%. Treatment of CBF-AML with fludarabine, high-dose cytarabine, and gemtuzumab ozogamicin (GO) results in estimated 10-year survival rates of ≥75%. In younger/fit patients, the "3+7" regimen (3 days of daunorubicin + 7 days of cytarabine) produces less favorable results (estimated 5-year survival rates of 35%; worse in real-world experience); regimens that incorporate high-dose cytarabine, adenosine nucleoside analogs, and GO are producing better results. Adding venetoclax, FLT3, and IDH inhibitors into these regimens has resulted in encouraging preliminary data. In older/unfit patients, low-intensity therapy with hypomethylating agents (HMAs) and venetoclax is now the new standard of care. Better low-intensity regimens incorporating cladribine, low-dose cytarabine, and other targeted therapies (FLT3 and IDH inhibitors) are emerging. Maintenance therapy now has a definite role in the treatment of AML, and oral HMAs with potential treatment benefits are also available. In conclusion, AML therapy is evolving rapidly and treatment results are improving in all AML subsets as novel agents and strategies are incorporated into traditional AML chemotherapy. LAY SUMMARY: Ongoing research in acute myeloid leukemia (AML) is progressing rapidly. Since 2017, the US Food and Drug Administration has approved 10 drugs for different AML indications. This review updates the research and treatment pathways for AML.
Subject(s)
Leukemia, Myeloid, Acute/drug therapy , Age Factors , Antineoplastic Agents/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Arsenic Trioxide/therapeutic use , Bridged Bicyclo Compounds, Heterocyclic/therapeutic use , Cladribine/therapeutic use , Core Binding Factors , Cytarabine/therapeutic use , Daunorubicin/therapeutic use , Gemtuzumab/therapeutic use , Humans , Leukemia, Myeloid, Acute/etiology , Leukemia, Myeloid, Acute/genetics , Leukemia, Myeloid, Acute/mortality , Leukemia, Promyelocytic, Acute/drug therapy , Leukemia, Promyelocytic, Acute/mortality , Maintenance Chemotherapy , Mutation , Myelodysplastic Syndromes/complications , Myeloproliferative Disorders/complications , Neoplasm, Residual , Sulfonamides/therapeutic use , Survival Rate , Translational Research, Biomedical , Tretinoin/therapeutic use , Vidarabine/analogs & derivatives , Vidarabine/therapeutic useABSTRACT
This review reflects the presentations and discussion at the 14th post-American Society of Hematology (ASH) International Workshop on Chronic Myeloproliferative Malignancies, which took place on the December 10 and 11, 2019, immediately after the 61st ASH Annual Meeting in Orlando, Florida. Rather than present a resume of the proceedings, we address some of the topical translational science research and clinically relevant topics in detail. We consider how recent studies using single-cell genomics and other molecular methods reveal novel aspects of hematopoiesis which in turn raise the possibility of new therapeutic approaches for patients with myeloproliferative neoplasms (MPNs). We discuss how alternative therapies could benefit patients with chronic myeloid leukemia who develop BCR-ABL1 mutant subclones following ABL1-tyrosine kinase inhibitor therapy. In MPNs, we focus on efforts beyond JAK-STAT and the merits of integrating activin receptor ligand traps, interferon-α, and allografting in the current treatment algorithm for patients with myelofibrosis.
Subject(s)
Disease Susceptibility , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/etiology , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/therapy , Myeloproliferative Disorders/etiology , Myeloproliferative Disorders/therapy , Anemia/diagnosis , Anemia/etiology , Anemia/therapy , Biomarkers , Biomarkers, Tumor , Combined Modality Therapy/adverse effects , Combined Modality Therapy/methods , Disease Management , Drug Development , Humans , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/complications , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis , Molecular Diagnostic Techniques , Molecular Targeted Therapy , Myeloproliferative Disorders/complications , Myeloproliferative Disorders/diagnosis , Prognosis , Single-Cell Analysis/methods , Translational Research, Biomedical , Treatment OutcomeABSTRACT
At present, very few data are available on deferasirox (DFX) in the treatment of patients with Philadelphia-negative myeloproliferative neoplasms in fibrotic phase (FP-MPN) and transfusion dependence. To address this issue, a retrospective analysis of 28 patients (22 male and 6 female) with FP-MPN and iron overload secondary to transfusion dependence was performed, based on patients enrolled in the database of our regional cooperative group who received treatment with DFX. DFX was started after a median interval from diagnosis of 12.8 months (IR 7.1-43.1) with median ferritin values of 1415 ng/mL (IR 1168-1768). Extra-hematological toxicity was reported in 16 of 28 patients (57.1%), but only two patients discontinued treatment due to toxicity. Among 26 patients evaluable for response (≥6 months of treatment), after a median treatment period of 15.4 months (IR 8.1-22.3), 11 patients (42.3%) achieved a stable and consistent reduction in ferritin levels <1000 ng/mL. As for hematological improvement, 6 of 26 patients (23%) showed a persistent (>3 months) rise of Hb levels >1.5 g/dL, with disappearance of transfusion dependence in four cases. Treatment with DFX is feasible and effective in FP-MPN with iron overload. Moreover, in this setting, an erythroid response can occur in a significant proportion of patients.
Subject(s)
Benzoates/therapeutic use , Erythropoiesis/drug effects , Iron Chelating Agents/therapeutic use , Iron Overload/drug therapy , Iron Overload/etiology , Myeloproliferative Disorders/complications , Myeloproliferative Disorders/pathology , Triazoles/therapeutic use , Aged , Benzoates/administration & dosage , Benzoates/adverse effects , Chelation Therapy , Deferasirox , Erythrocyte Indices , Female , Fibrosis , Follow-Up Studies , Humans , Iron Chelating Agents/administration & dosage , Iron Chelating Agents/adverse effects , Iron Overload/blood , Iron Overload/diagnosis , Male , Middle Aged , Myeloproliferative Disorders/mortality , Myeloproliferative Disorders/therapy , Retrospective Studies , Transfusion Reaction , Treatment Outcome , Triazoles/administration & dosage , Triazoles/adverse effectsABSTRACT
El manejo convencional de los síndromes mieloproliferativos crónicos (SMP) es un problema cuya frecuencia se ha incrementado. Los datos existentes en la literatura provienen principalmente de series de casos. Esta serie reporta la evolución y el tratamiento de 9 embarazos en 7 pacientes con SMP, 4 con diagnóstico de leucemia mieloide crónica (LMC) y 3 con trombocitemia esencial (TE) asistidos en nuestro Departamento durante los últimos 20 años. La evolución del primer embarazo incluyó: nacido vivo a término 29 por ciento, aborto espontáneo 14 por ciento, nacido vivo pretérmino 29 por ciento y desconocida 14 por ciento. Un embarazo está en curso (14 por ciento). No se registraron muertes fetales. Las complicaciones maternas fueron: sangrado en una paciente con LMC y desprendimiento placentario en otro caso con TE. La segunda gestación resultó en un nacido vivo pretérmino (N=1) y otra está en curso. Todas las pacientes con TE recibieron interferón alta y aspirina durante el embarazo y profilaxis con enoxaparina durante el puerperio. Las pacientes con LMC recibieron: interferón alfa (N=1), hidroxiurea luego del primer trimestre e interferón alfa (N= 1) e imatinib durante el primer trimestre y nilotinib en el tercero la tercer paciente, dando a luz un feto vivo normal. Un mayor número de casos sería necesario para establecer factores pronósticos en este grupo de pacientes.
Chronic myeloproliferative syndromes and pregnancy. A case review of Clinical Hematological Department patients. The management of pregnancy in chronic myeloproliferative disorders (CMPD) is an increasingly frequent problem. Available data in the literature belong to case reports or single centers series. In the current study we report the outcome and treatment of 9 pregnancies among 7 patients with CMPD, 4 with chronic myeloid leukemia (CML) and 3 with essential thrombocythemia (ET) seen in our Department from 1989 to 2009. First pregnancy outcome included full term normal delivery 29 per cent, spontaneous abortion 14 per cent, premature delivery 29 per cent and unknown 14 per cent. No stillbirth was recorded and one pregnancy is currently ongoing. Maternal complications included: bleeding in one CML patient and abruptio placentae in a TE patient. Among second pregnancies, 1 is ongoing and the other resulted in premature delivery. AII TE patients received alpha interferon and aspirin during pregnancy. Prophylaxis with enoxaparin was administered for six weeks postpartum. CML patient were treated as follows: alpha interferon (N=1), hydroxyurea after first trimester plus alpha interferon (N=1). The remaining patient received imatinib and nilotinib giving birth to a normal baby. Further study is necessary to evaluate prognostic factors in these patients.
Subject(s)
Humans , Adult , Female , Pregnancy , Pregnancy Complications, Hematologic , Myeloproliferative Disorders/complications , Myeloproliferative Disorders/therapy , Chronic Disease , Clinical Evolution , Clinical Laboratory Techniques , /genetics , Leukemia, Myelogenous, Chronic, BCR-ABL Positive , Thrombocythemia, EssentialABSTRACT
Hyperhomocysteinemia is an established risk factor for thrombosis. In patients with myeloproliferative disorders, thrombotic events are common. Our aim was to investigate whether the increased burden of proliferating cells present in these patients implies a risk of homocysteine (HCY) accumulation secondary to depletion of folate and/or cobalamin. Fifty patients (PV, 25; ET, 10; IMF, 15) and 163 healthy volunteers (HV) participated in the study. The prevalence of hyperhomocysteinemia was 56.0% in PV, 70.0% in ET, 60.0% in IMF, and 34.9% in HV. The mean P-homocysteine (P-HCY) was 13.88 +/- 4.24 micromol/L in PV, 12.78 +/- 3.70 in ET, 11.34 +/- 4.22 in IMF, and 9. 71 +/- 2.76 in HV. In PV and ET, but not in IMF, the mean P-HCY was significantly higher than in the HV group (P < 0.001, P = 0.028, and P = 0.163, respectively). Thirty-three percent of the patients with hyperhomocysteinemia displayed metabolic changes compatible with cobalamin deficiency (P-HCY and P-methylmalonic acid both elevated), while 67% were folate deficient (P-HCY elevated, P-methylmalonic acid normal). Supplementation therapy with the relevant vitamin was implemented in 11 vitamin-deficient patients and led to normalization of metabolite levels in all cases. No correlation between hyperhomocysteinemia and thrombosis was found. Our data indicate that patients with PV, ET, and IMF frequently develop hyperhomocysteinemia due to discrete depletion of cobalamin or folate. Vitamin therapy leads to normalization of P-HCY and should be considered, even though hyperhomocysteinemia does not seem to be of crucial importance for the thrombotic tendency in the myeloproliferative disorders.
Subject(s)
Folic Acid Deficiency/complications , Hyperhomocysteinemia/complications , Hyperhomocysteinemia/epidemiology , Myeloproliferative Disorders/blood , Myeloproliferative Disorders/complications , Vitamin B 12 Deficiency/complications , Adult , Age Factors , Aged , Aged, 80 and over , Chronic Disease , Female , Folic Acid Deficiency/blood , Folic Acid Deficiency/drug therapy , Humans , Male , Middle Aged , Polycythemia Vera/blood , Polycythemia Vera/complications , Prevalence , Primary Myelofibrosis/blood , Primary Myelofibrosis/complications , Regression Analysis , Risk Factors , Thrombocythemia, Essential/blood , Thrombocythemia, Essential/complications , Thrombosis/blood , Thrombosis/etiology , Vitamin B 12 Deficiency/blood , Vitamin B 12 Deficiency/drug therapy , Vitamins/administration & dosageABSTRACT
A 60-year-old woman was admitted with mild intestinal obstruction. Enteroclysis showed segmental narrowing with mucosal fold thickening of the proximal jejunum. Computed tomography in addition demonstrated enlarged mesenteric lymph nodes in the proximity of the diseased intestinal loop. Histological examination of the resected intestinal segment showed extramedullary hemopoiesis. Bone marrow examination confirmed myeloproliferative syndrome.